Antibody-Mediated Status Epilepticus: A Retrospective Multicenter Survey

Franz Josef Holzer a  Andrea O. Rossetti b  Anne-Chantal Heritier-Barras a  Dominik Zumsteg c  Robert Roebling d  Roman Huber d  Holger Lerche d, e  Ines C. Kiphuth f  Jürgen Bardutzky f  Christian G. Bien g  Mathias Tröger h  Gaby Schoch h  Harald Prüss i  Margitta Seeck a

a Department of Neurology, University Hospital, Geneva, b Department of Neurology, University Hospital, Lausanne, and c Department of Neurology, University Hospital, Zürich, Switzerland; d Department of Neurology, Universitätssklinikum, Ulm, e Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Tübingen, f Department of Neurology, University of Erlangen-Nuremberg, Erlangen, and g Department of Epileptology, University of Bonn Medical Centre, Bonn, Germany; h Department of Neurology, Inselspital, Bern, Switzerland; i Department of Neurology, Charité University Medicine, Berlin, Germany

Key Words
Status epilepticus · Autoimmune encephalitis · Antiepileptics · Immunomodulatory treatment · Patient outcome

Abstract
Background: In recent years, an increasing number of autoantibodies (AB) have been detected in the CSF and serum of patients with new onset epilepsy. Some of these patients develop convulsive or nonconvulsive status epilepticus (AB-SE), necessitating intensive medical care and administration of multiple antiepileptic and immunomodulatory treatments of uncertain effectiveness. Objectives: In this retrospective multicenter survey we aimed to determine the spectrum of gravity, the duration and the prognosis of the disorder. In addition, we sought to identify the antibodies associated with this condition, as well as determine whether there is a most effective treatment regime. Methods: 12 European Neurology University Clinics, with extensive experience in the treatment of SE patients, were sent a detailed questionnaire regarding symptoms and treatment of AB-SE patients. Seven centers responded positively, providing a total of 13 patients above the age of 16. Results: AB-SE affects mainly women (12/13, 92%) with a variable age at onset (17–69 years, median: 25 years). The duration of the disease is also variable (10 days to 12 years, median: 2 months). Only the 3 oldest patients died (55–69 years). Most patients were diagnosed with anti NMDAR encephalitis (8/13) and had oligoclonal bands in the CSF (9/13). No specific treatment regimen (antiepileptic, immunomodulatory) was found to be clearly superior. Most of the surviving 10 patients (77%) recovered completely or nearly so within 2 years of index poststatus. Conclusion: AB-SE is a severe but potentially reversible condition. Long duration does not seem to imply fatal outcome; however, age older than 50 years at time of onset appears to be a risk factor for death. There was no evidence for an optimal antiepileptic or immunomodulatory treatment. A prospective multicenter study is warranted in order to stratify the optimal treatment algorithm, determine clear risk factors of unfavorable outcome and long-term prognosis.

Received: December 21, 2011
Accepted: June 17, 2012
Published online: October 10, 2012
Introduction

In the last few years, an increasing number of auto-
antisera has been detected in patients with new onset
epilepsy, leading to the concept of a subgroup of epilepsy
as an autoimmune disease [1–3]. Some auto-
antisera (AB) like those directed to glutamic acid
decarboxylase (GAD-
AB, associated with stiff-person syndrome and epilepsy)
seem to be of autoimmune origin, others like anti-Hu of
paraneoplastic, whereas NMDAR-AB can be of either
origin [4]. It is hypothesized that some of these antibod-
ies modulate the equilibrium between excitatory and in-
hibitory mechanisms in the central nervous system, ei-
ther by targeting ion channels (e.g. antibodies against
N-methyl-D-aspartate receptor; NMDAR-AB [5]) or key
enzymes (e.g. antibodies against GAD, the enzyme
which converts glutamic acid into gamma aminobutyric
acid [6]), leading to a gain of excitability or a lack of in-
hibition and consequently resulting in seizures, among
other symptoms.

Some of these patients with AB develop status epilep-
ticus (AB-SE) [7], convulsive or nonconvulsive, and
require prolonged intensive care, mechanical ventila-
tion and multiple antiepileptic and immunomodulatory
treatments [8, 9]. To date, there are no good data about
the ultimate outcome of these patients. There is also
sparse knowledge about the most effective treatments.
It is therefore important to comprehensively investigate
the clinical characteristics and course of AB-SE and
whether there is a uniquely successful treatment regi-
men.

Methods

We sent a detailed questionnaire to 12 European Neurology
University Clinics, with extensive experience in the treatment of
SE. The study was limited to patients older than 16 years. Seven
centers responded positively (Berne, Lausanne, Zurich, Berlin,
Bonn, Erlangen, Ulm), providing a total of 13 patients, including
our 2 patients (Geneva), diagnosed with AB-SE between 2003 and
2011.

We inquired about patient characteristics, clinical features,
history of neoplasia or autoimmune disease, duration of SE (ta-
ble 1), antibodies and paraclinical findings including imaging,
results of CSF and ictal and interictal EEG (table 2) and adminis-
tered treatments and outcome (table 3).

There is no universally accepted definition of nonconvulsive
status epilepticus (NCSE); however, all our patients showed ab-
normal, focal, or multifocal or generalized rhythmic activity, with
evolution in frequency, morphology and field (except in 1 patient
where judgment was based purely on the clinical picture).

Results

Clinical Findings

Patients were aged from 17 to 69 years; the mean age
was 32.5 years (17–69 years, median 25 years). There was
a high female-male ratio (12/13; 92%).

One patient presented prodromal, unspecific symp-
toms, such as fatigue or headache before the occurrence
of status epilepticus (SE), neuropsychiatric symptoms in-
cluding behavioral changes, memory loss, agitation and
psychosis, or isolated simple, complex partial or general-
ized epileptic seizures were found in 12 patients. Alto-
gether, 12 of 13 had more or less significant clinical symp-
toms before AB-SE occurred.

When hospitalized for SE, 3 patients were found to
have an underlying neoplastic disease (23%: 2 ovarian
teratoma and 1 small cell lung cancer); whereas in 2 oth-
er patients an ovarian teratoma was diagnosed only later,
i.e. 1 and 2 years, respectively, after complete recovery
(total of patients with tumor 38%). One patient suffered
from steroid-responsive encephalitis associated with thy-
roiditis (Hashimoto).

The latencies between the first symptoms and the on-
set of status epilepticus varied from 0 to 11 months. In
7/13 patients (53%), SE was present within the first week
of symptoms. In the other half (47%), the delay between
onset and SE was between 1 week and 11 months (mean
3.3 months, median 1 month).

Duration of SE varied considerably from 2 h to 12
years, in 3 cases less than a month (2 h, 10 and 18 days,
respectively), in 1 case 12 years (patient 5), but in the ma-
majority (9 of 13) SE lasted between 1 and 4 months. Nine
patients needed pharmacological coma induction and
mechanical ventilation, independently of duration or
type of AB.

The majority of our patients (70%) had either complex
partial (7/13), or generalized tonic-clonic seizures (5/13).
Only 1 patient presented with simple partial seizures.

Paraclinical Findings

Serum

Serum antibodies against NMDA receptor were most
frequently associated with SE, found in 8 of 13 patients
(61%; patients 1, 2, 5, 7, 8, 9, 10 and 12). Except in patient
8, where it was not specifically tested, all patients with
these serum antibodies also had NMDAR-AB in the ce-
rebrospinal fluid.

Antibodies against GAD were found in 1 patient (No.
11, also positive in the CSF), and against hippocampal
neuropil without further specification of the reactivity
(negative for all known antigenic specificities, No. 13) in another patient, whereas in 2 patients (Nos. 3 and 6) the testing for any of these serum antibodies was negative. However, in these 2 patients, oligoclonal bands in the CSF indicated autoimmune origin. Patient 6 had none of these serum antibodies, but antibodies against GluR3 in the CSF were present. In patient 4 Ri-AB was found in the serum, but not in the CSF.

Cerebrospinal Fluid
Oligoclonal bands were found in 9/13 patients (69%), including NMDAR-AB and non-NMDAR-AB patients. White blood cell counts (WBC) were also elevated in most patients (in 11 of 13 patients; 85%), ranging from 6 to 134 million/l. Only patient 6 with anti-GluR3 and patient 11 with GAD-AB had normal WBC. Abnormally elevated CSF protein levels were found in 4 patients (30%).

Table 1. Patients and clinical features

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Reference center</th>
<th>Gender</th>
<th>Age at onset years</th>
<th>First symptoms</th>
<th>Neoplasia or other diseases</th>
<th>Beginning of epilepsy after onset of first symptoms</th>
<th>Type of epilepsy</th>
<th>Duration of status epilepticus</th>
<th>Intubation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Geneva</td>
<td>M</td>
<td>58</td>
<td>headache, disinhibition, aggressivity, short term memory loss</td>
<td>none</td>
<td>6 months</td>
<td>facial and upper limbs myoclonus (CP)</td>
<td>4 months</td>
<td>yes</td>
</tr>
<tr>
<td>2</td>
<td>Geneva</td>
<td>F</td>
<td>22</td>
<td>dizziness, disorientation, amnesia, agitation, epileptic seizure</td>
<td>ovarian teratoma discovered 1 year after full recovery</td>
<td>1 week</td>
<td>NCSE</td>
<td>2 months</td>
<td>yes</td>
</tr>
<tr>
<td>3</td>
<td>Berne</td>
<td>F</td>
<td>55</td>
<td>loss of energy, restlessness, short term memory loss</td>
<td>none</td>
<td>11 months</td>
<td>GTCS</td>
<td>10 days</td>
<td>yes</td>
</tr>
<tr>
<td>4</td>
<td>Lausanne</td>
<td>F</td>
<td>69</td>
<td>generalized clonic and CP seizures, progressive obtundation</td>
<td>small cell lung cancer</td>
<td>0 months</td>
<td>GC and CP seizures</td>
<td>26 days (1 month)</td>
<td>yes</td>
</tr>
<tr>
<td>5</td>
<td>Lausanne</td>
<td>F</td>
<td>25</td>
<td>fatigue, somnolence, dysphasia</td>
<td>none</td>
<td>3 weeks</td>
<td>GC and CP seizures</td>
<td>3 months</td>
<td>no</td>
</tr>
<tr>
<td>6</td>
<td>Lausanne</td>
<td>F</td>
<td>28</td>
<td>SP seizures</td>
<td>none</td>
<td>0 months</td>
<td>SP seizures</td>
<td>12 years</td>
<td>yes</td>
</tr>
<tr>
<td>7</td>
<td>Zurich</td>
<td>F</td>
<td>37</td>
<td>psychosis, disorientation, agitation, dysphagia, dysarthria</td>
<td>ovarian teratoma</td>
<td>0 months</td>
<td>NCSE</td>
<td>4 months</td>
<td>yes</td>
</tr>
<tr>
<td>8</td>
<td>Zurich</td>
<td>F</td>
<td>36</td>
<td>psychosis, depression, insomnia, dyslexia</td>
<td>none</td>
<td>0 months</td>
<td>NCSE</td>
<td>4 months</td>
<td>yes</td>
</tr>
<tr>
<td>9</td>
<td>Berlin</td>
<td>F</td>
<td>19</td>
<td>headache, epileptic seizure, disorientation, anxiety, irritability</td>
<td>ovarian teratoma</td>
<td>0 months</td>
<td>GTCS</td>
<td>2 h</td>
<td>no</td>
</tr>
<tr>
<td>10</td>
<td>Bonn</td>
<td>F</td>
<td>17</td>
<td>GTCS</td>
<td>none</td>
<td>0 months</td>
<td>GTCS</td>
<td>18 days</td>
<td>no</td>
</tr>
<tr>
<td>11</td>
<td>Erlangen</td>
<td>F</td>
<td>21</td>
<td>dystonia</td>
<td>Hashimoto</td>
<td>1 month</td>
<td>CP seizures</td>
<td>2 and 3 months</td>
<td>yes</td>
</tr>
<tr>
<td>12</td>
<td>Ulm</td>
<td>F</td>
<td>17</td>
<td>psychosis, agitation, seizures, amnesia</td>
<td>none</td>
<td>1 month</td>
<td>GTCS</td>
<td>5 weeks</td>
<td>yes</td>
</tr>
<tr>
<td>13</td>
<td>Ulm</td>
<td>F</td>
<td>19</td>
<td>psychosis, agitation, seizures, amnesia, incontinence, mild dyskinesia</td>
<td>ovarian teratoma discovered 2 years after full recovery</td>
<td>0 months</td>
<td>GTCS</td>
<td>intermittent for a few weeks</td>
<td>no</td>
</tr>
</tbody>
</table>

NCSE = Nonconvulsive status epilepticus; GTCS = generalized tonic-clonic seizures; GC = generalized clonic; CP = complex partial; SP = simple partial.
### Table 2. Antibodies and paraclinical findings

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>AB in serum</th>
<th>AB in CSF</th>
<th>Brain MRI</th>
<th>FDG-PET</th>
<th>CSF</th>
<th>Interictal EEG</th>
<th>Ictal EEG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>normal, then diffuse atrophy</td>
<td>severe parieto-temporo-occipital and basal ganglia hypometabolism</td>
<td>WBC: 100; prot: 1 g/l; OB: positive (type 2)</td>
<td>continuous monomorph theta, areactive</td>
<td>NCSE (left temporal, right frontal)</td>
</tr>
<tr>
<td>2</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>normal</td>
<td>WBC: 134; prot: 0.37 g/l; OB: positive (type 2)</td>
<td>diffuse polymorph delta slowing</td>
<td>rhythmic diffuse monomorph delta slowing</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>no AB detected</td>
<td>no AB detected</td>
<td>normal, then T2 hyperintensity in bilateral hippocampus</td>
<td>WBC: 15; prot: 1.6 g/l; OB: positive (type 2)</td>
<td>severe general slowing</td>
<td>continuous frontal sharp slow waves</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Ri-AB (1/1,280)</td>
<td>no AB detected</td>
<td>multifocal T2 hyperintensity</td>
<td>WBC: 6; prot: 0.68 g/l; OB: positive</td>
<td>diffuse theta-delta, irregular slowing</td>
<td>multifocal, bilaterally independent seizures</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>normal, then minimal diffuse atrophy</td>
<td>striatal hypermetabolism</td>
<td>WBC: 27; prot: 0.37 g/l; OB: positive</td>
<td>diffuse theta-delta slowing</td>
<td>rhythmic anterior delta, waxing and waning</td>
</tr>
<tr>
<td>6</td>
<td>no AB detected</td>
<td>anti-GLUR3</td>
<td>progressive, focal right parietal atrophy</td>
<td>multifocal T2 hyperintensity</td>
<td>WBC: 79; prot: 0.61 g/l; OB positive</td>
<td>continuous theta/ delta, areactive</td>
<td>NCSE bifrontotemporal, predominant delta rhythms</td>
</tr>
<tr>
<td>7</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>normal (DVA frontal sup. gyrus)</td>
<td>bifrontal and bithalamic hypermetabolism</td>
<td>WBC: 37; prot: 0.48 g/l; OB: positive</td>
<td>continuous monomorph delta, areactive</td>
<td>multifocal NCSE, initially bitemporal independent, later bifrontal</td>
</tr>
<tr>
<td>8</td>
<td>NMDAR-AB</td>
<td>not done</td>
<td>normal, repeatedly</td>
<td>hypometabolism bioccipital and in motor cortex bilateral, later normalized</td>
<td>WBC: 79; prot: 0.61 g/l; OB positive</td>
<td>continuous theta/ delta, areactive</td>
<td>NCSE bifrontotemporal, predominant delta rhythms</td>
</tr>
<tr>
<td>9</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>normal, then subtle grey matter enhancement in medial temporal lobes and gyrus cinguli</td>
<td>left normalized</td>
<td>WBC: 39; prot: 0.39 g/l; OB: positive</td>
<td>marked slowing and epileptic activity (generalized)</td>
<td>not performed</td>
</tr>
<tr>
<td>10</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>status related, later on regressive bilateral cortical signal increase</td>
<td>normal, repeatedly</td>
<td>WBC: 40; prot: 0.31 g/l; OB: positive</td>
<td>diffuse theta slowing</td>
<td>right hemispheric status</td>
</tr>
<tr>
<td>11</td>
<td>GAD-AB</td>
<td>anti-GAD</td>
<td>initially normal, then bitemporal hyperintensive lesion</td>
<td>multifocal bitemporal</td>
<td>WBC: 2; prot: normal, lactate: 2.2 mmol/l</td>
<td>alpha EEG</td>
<td>theta, ETPs</td>
</tr>
<tr>
<td>12</td>
<td>NMDAR-AB</td>
<td>NMDAR-AB</td>
<td>normal, repeatedly</td>
<td>normal, repeatedly</td>
<td>WBC: 40; OB: negative</td>
<td>irregular theta to delta, no ETPs</td>
<td>bifrontal and generalized</td>
</tr>
<tr>
<td>13</td>
<td>unclassified AB</td>
<td>not done</td>
<td>against hippocampal neuropil</td>
<td>normal, repeatedly</td>
<td>WBC: 40; OB: negative</td>
<td>irregular theta to delta, no ETPs</td>
<td>bifrontal and generalized</td>
</tr>
</tbody>
</table>

GLUR3-AB = Antiglutamate receptor 3-AB; GAD-AB = glutamic acid decarboxylase-AB; Ri-AB = antineuronal nuclear autoantibody type 2-AB (i.e. ANNA-2); DVA = developmental venous anomaly; ETPs = epilepsy-typical potentials; OB = oligoclonal bands; WBC = white blood cells (normal: 0–3).
independent of the type of AB. Overall, 4 patients had no oligoclonal bands (Nos. 6, 11, 12 and 13).

EEG
Interictal EEG findings generally showed theta or delta slowing (12 of 13 patients). Only patient 11 with GAD-AB had a normal interictal EEG. Given that patients were in SE, ictal recordings were obtained in all but 1 patient (No. 9). In this patient (NMDAR-AB), no ictal EEG was obtained due to the short duration of SE. In the remaining, ictal EEG revealed frontal or fronto-temporal seizure onset in 7 patients (54%, Nos. 1, 3, 5, 6, 10, 12 and 13), multifocal in 1 (No. 4), and nonconvulsive epileptic status in 3 patients (Nos. 2, 7 and 8, all NMDAR-AB). Patient 11 (GAD-AB) showed generalized slowing with epileptiform discharges (fig. 1).

Brain Imaging
MRI was initially normal in 10 patients (77%), and remained normal in 5 (patients 2, 7, 8, 12 and 13). Cortical,

Table 3. Treatments and outcome

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Inefficient AED</th>
<th>Efficient AED</th>
<th>Steroids PE i.v.</th>
<th>IvIg</th>
<th>CPM</th>
<th>RTM</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>LEV + PB + VPA</td>
<td>none</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>death</td>
</tr>
<tr>
<td>2</td>
<td>LEV + VPA + CLP + PRO</td>
<td>none</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>nearly restitutio ad integrum (mild dysexecutive disorders)</td>
</tr>
<tr>
<td>3</td>
<td>LEV, LTG, VPA</td>
<td>none</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>death</td>
</tr>
<tr>
<td>4</td>
<td>CLZ, LEV, LZP, PHT, TPM, THP</td>
<td>none</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>death</td>
</tr>
<tr>
<td>5</td>
<td>LEV, CBZ, LZP, TPM, THP, MDZ, KTM, LCS</td>
<td>PRO + PB + PGB + PHT</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>nearly restitutio ad integrum (mild memory dysfunction)</td>
</tr>
<tr>
<td>6</td>
<td>PB, CBZ, VPA, VGV, PHT, TPM, GBP, PRO</td>
<td>PGB + LTG + LEV + CLZ + VNS</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>markedly reduced seizure intensity (after VNS)</td>
</tr>
<tr>
<td>7</td>
<td>PHT, VPA, MDZ, THP, LTG, LEV, TPM, CLB</td>
<td>none</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>nearly restitutio ad integrum</td>
</tr>
<tr>
<td>8</td>
<td>VPA, LZP, MDZ, PRO, PHT, PB, CLB, TPM, LEV, THP, FBM</td>
<td>none</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>severe deficits (cognitive, physical, remains dependent)</td>
</tr>
<tr>
<td>9</td>
<td>LEV, DZP</td>
<td>Lzp + PRM</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>restitutio ad integrum</td>
</tr>
<tr>
<td>10</td>
<td>PHT, VPA, VPA + CLB</td>
<td>GBP + PB + PHT + VPA</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>nearly restitutio ad integrum</td>
</tr>
<tr>
<td>11</td>
<td>PHT, VPA</td>
<td>CLP + GBP + LEV + Lzp + PRM</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>hearing impairment, no cognitive deficits</td>
</tr>
<tr>
<td>12</td>
<td>LEV, PHT, TPM, VPA</td>
<td>PB (partially)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>restitutio ad integrum (after 2 years)</td>
</tr>
<tr>
<td>13</td>
<td>LZP, LEV, PHT</td>
<td>none</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>restitutio ad integrum (after 1 year)</td>
</tr>
</tbody>
</table>

CBZ = Carbamazepine; CLB = clobazam; CLP = clonazepam; CLZ = clorazepate; DZP = diazepam; FBM = felbamate; GBP = gabapentine; KTM = ketamine; LTG = lamotrigine; LEV = levetiracetam; LCS = lacosamide; LZP = lorazepam; MDZ = midazolam; PB = phenobarbital; PHT = phenytoin; PGB = pregabalin; PRM = primidone; PRO = propofol; THP = thiopental; TPM = topiramate; VGV = vigabatrin; VPA = valproic acid; PE = plasmapheresis; IvIg = intravenous immunoglobulin; CPM = cyclophosphamide; RTM = rituximab; VNS = vagus nerve stimulation.
hippocampal and temporal signal increase was found in 4 (patients 3, 9, 10 and 11). Patients 1 and 5 with initially normal MRI showed subsequently diffuse atrophy. In patient 6 with GluR3-AB, a focal right parietal atrophy appeared after 2 years (histologically confirmed adult Rasmussen encephalitis, recently reported [10]).

Cerebral FDG-PET scan was done in 4 patients (all with NMDAR-AB) and showed in patient 1 severe bilateral parietotempero-occipital and basal ganglia hypometabolism, in patient 6 striatal hypermetabolism correlating with disease course (recently reported [11]), in patient 7 bifrontal and bithalamic hypermetabolism, whereas in patient 8 bilateral hypometabolism spared the subcortical regions and was present in the occipital and motor cortex regions.

Treatments and Response

Classic antiepileptic and new-generation antiepileptic drugs (AED) individually or in combination have been used to control AB-SE, but with poor results. Phenytoin, valproic acid and levetiracetam or their combination have consistently failed, despite dosages and serum levels in the recommended therapeutic range. In 7 patients (54%) there was no efficient AED at all, whereas 1 patient (No. 9) responded to lorazepam and primidone, 3 patients improved with a combination of 4 AED (Nos. 5, 6 and 10), and 1 (No. 11) with 5 AED.

Of the 8 patients who recovered completely or nearly completely, 3 of them (Nos. 9, 10 and 12, all NMDAR-AB) received steroids as the unique immunomodulatory treatment. Patient 5 (NMDAR-AB) responded with some delay to a combination of steroids, plasma exchange (PE) and Ivlg, or possibly spontaneously, patient 7 (NMDAR-AB) to steroids and Ivlg, whereas patient 13 (AB hippocampal neuropil) improved without any immunomodulatory treatment. Patient 6 (GluR3-AB) received steroids early in her illness, but improved somewhat only after VNS was implanted several years later. Patient 8 (NMDAR-AB) responded to steroids, PE, Ivlg and cyclophosphamide. Patient 11 (GAD-AB) did not receive steroids but transiently improved after PE and Ivlg, and finally recovered after cyclophosphamide.

Outcome

Eight patients of 13 (62%) recovered completely or nearly completely (Nos. 2, 5, 7 and 9–13), despite a mean duration of SE of 50 days (patient 11 remained with a hearing impairment but no other neurological or cognitive deficits). Only 2 of the 10 surviving patients remained severely disabled (patients 8 and 6 with adult Rasmussen encephalitis, but stabilized in his course). Recovery may be long and in some patients took more than 1–2 years (Nos. 12 and 13). Two patients are of special interest: patient 2 recovered after AED (with no response) and after immunomodulatory therapy; however, with persisting NMDAR-AB, an ovarian teratoma was found and operated only 1 year after full recovery. Patient 13, without any immunomodulatory treatment and without any re-
sponse to AED; this young female recovered spontaneously and completely over 1 year, but an ovarian teratoma was discovered and removed only 2 years later. Three patients died. Patient 1 (NMDAR-AB) died after several months of SE despite five different immunomodulatory treatments and without an underlying tumor disease. Patient 3, with no specific AB detected probably died from brain edema and autonomic dysfunction and the course was fulminant (10 days). Patient 4 died 26 days after onset (Ri-AB and small cell lung cancer) during SE.

**Discussion**

AB-SE is a rare, heterogeneous condition, and diagnosed on the basis of clinical features of encephalitis, EEG changes and laboratory results, requiring care in intensive care units (ICU). In our retrospective multicenter survey of 13 patients, we identified as potential risk factors female gender (12 of 13) and serum NMDAR-AB (8 of 13). The prevalence of autoimmune diseases in women is well known and possible explanations are provided in a recent review [12] (e.g. higher CD4+ lymphocytes, enhanced cytokine production in the presence of estrogen).

Pathophysiological mechanisms of epilepsy of autoimmune origin, or its most extreme form AB-SE, are not perfectly understood. In particular, it remains unclear as to whether the antibodies are pathogenic themselves or simply a marker of another directly pathogenic process. In any case, the treating physician aims to shorten that process by introducing immunomodulatory treatment.

In our patient group, there is no evidence for the best first-line treatment. Despite attempts to treat with various antiepileptic medications of different and complementary pharmacological characteristics, inconclusive outcomes have resulted with no evidence for a one most effective antiepileptic drug or combination therapy.

No straightforward picture emerged either regarding the immunomodulatory treatments. Ten patients received steroids, which did not help in 5/10. Interestingly, PE and IIVlg were given in less than 50% of the patients, despite a long SE duration in some of them (e.g. patients 4, 12 and 13). This may indicate a delayed referral to neurologists or immunologists and/or limited awareness of AB-SE within the ICU staff, delaying reinforcement of therapy. Overall, our study cannot confirm or invalidate the hypothesis that early and aggressive immunomodulatory treatment (e.g. steroids, PE, IIVlg, or their association) would change the course of the disease. As shown in previous studies [13, 14], the removal of an underlying tumor, if possible, is related to better outcome. However, this view is challenged by our observation. The condition of 2 patients recovered completely before the tumor was detected, indicating that even in a probable paraneoplastic context, conservative treatment may be sufficient.

AB-SE is a serious condition with high mortality (3 of 13, 23%). Interestingly, all the patients who died were also the oldest of our series (55, 58 and 69 years old). While a paraneoplastic origin was found in one of them, there was no evidence of an underlying tumor in the other 2 patients. DeLorenzo et al. [15] noted in 1996 that the ‘The prognosis of SE in adults is poorer than in children and particularly so in those over 60 years of age’. This difference was thought to be due to the underlying pathology. In the DeLorenzo data most of the older subjects suffered from brain anoxia or (larger) acute stroke, i.e. a pathology that is per se related to a poorer prognosis. However, several other papers underscore that age and etiology are the most important independent outcome predictors in SE [16]. It remains to be shown in further studies whether age will emerge as an independent risk factor in AB-SE or if other factors, such as less aggressive therapy in older patients, determine this unfavorable outcome.

ABs to intracellular antigens may be associated with bad response to immunomodulatory treatment and poorer outcome, whereas ABs to extracellular antigens are believed to have a better prognosis. Our case series does not confirm this hypothesis. Of our 3 patients with a fatal outcome, only 1 had AB against an intracellular antigen (patient 4, Ri-AB), while another had AB against an extracellular antigen (patient 1, NMDAR-AB), and in 1 patient there was no known AB at all. Furthermore, 1 patient with a good outcome (patient 11) had an AB against intracellular antigen (GAD-AB).

In a recent study on 7 ICU patients with NMDAR-AB [17], with an age range from 19 to 31, the outcome was favorable in all of them. Another 6 ICU patients with NMDAR-AB and encephalitis, with an age range from 20 to 41, were reported in a recent cohort study [18]. Half of them had a slow but good recovery, 2 were left with severe neurological deficits and 1, the oldest of the cohort, succumbed to pneumonia 6 months after onset. Thus the outcome remains variable and unpredictable, even if the type of AB and the age range are comparable.

It is of note that most patients survived and 62% (8/13) with good-to-excellent neurological and cognitive outcome, although recovery in some cases took up to two years. Outcome was independent of the duration of sta-
tus, i.e. even with AB-SE of several months, there was a good chance for full or almost full recovery. This is exemplified by patients 5 and 7, who were in SE for 3 and 4 months, respectively, but eventually recovered almost completely. This is an important observation, given the recent sharp increase in the description of autoimmune epilepsy and AB-SE in the literature, there is still no established algorithm of treatment strategy. Prospective multicenter studies are needed to determine optimal treatment, and whether early and aggressive immunomodulatory therapy prevents fatal outcome and/or shortens significantly the ICU stay. An additional point to consider is also that early treatment requires fast laboratory confirmation of relevant AB in high titer. Furthermore, increased awareness of this often reversible condition (SE of unclear origin, with a history of neuropsychiatric or infectious symptoms) is mandatory to shorten the delay to proper diagnosis and treatment.

Acknowledgements

Supported by a grant from the Swiss National Science Foundation: SPUM 33CM30–14032.

References